ETPN General Assembly Grenoble, October 1 st, Overview of Bracco Imaging & the ETPN membership role

Size: px

Start display at page:

Download "ETPN General Assembly Grenoble, October 1 st, Overview of Bracco Imaging & the ETPN membership role"

Myles Cox
6 years ago
Views:

1 ETPN General Assembly Grenoble, October 1 st, 2013 Overview of Bracco Imaging & the ETPN membership role 1

Group Organization A private, Italian multinational operating through 4 Business

PRESCRIPTION DRUGS CDI ITALIAN DIAGNOSTIC CENTER An international leader in imaging

2 Group Organization A private, Italian multinational operating through 4 Business Units BRACCO SPA Holding - Milan (Italy) BRACCO IMAGING GROUP ACIST PHARMA OTC PRESCRIPTION DRUGS CDI ITALIAN DIAGNOSTIC CENTER An international leader in imaging diagnostics with a wide range of products and solutions for all diagnostic modalities. Leader in systems for administering contrast agents and advanced medical devices with registered offices in the USA. Development, manufacture and distribution in Italy of prescription drugs, over-the-counter (OTC) drugs and food supplements. Health Services. Customized prevention, diagnosis, rehabilitation and therapeutic services. 2

3 Bracco Group sales Contrast agents and related activities: 810 M Euro Contrast agents Injectors: 108 M Euro Pharma products: 159 M Euro Healthcare Services: 84 M Euro Europe: 544 M Euro North America: 426 M Euro Rest of the world: 191 M Euro 3

4 Our journey at a glance First established as a pharmaceutical Company in 1927, over the years Bracco has intensified its commitment to innovative research and specialized in contrast agents for medical diagnostics Elio Bracco established the Italian E. Merck company in Milan 1946 The first in-house Research Center was set up at the new laboratories in Milan 1959 The Production Unit in Milan (Lambrate site), was opened, growing larger and larger over the years Launch of Iopamidol, the first non-ionic, ready for use contrast agent, in Italy and Germany 1989 Contrast agents were launched on the market, produced by Cilag, Jadobil & Joduron Establishment of the Bracco - Eisai joint venture in Japan Opening of Bracco Far East Ltd in Hong Kong and Bracco UK Acquisition of ACIST Medical Systems Opening of Shanghai Bracco Sine, a joint venture in China (in 2004 opening of the Bracco Sine Production Unit) The merger of the Società Bracco, già Italmerck with the Industria Chimica Dott. Fulvio Bracco gave birth to the Bracco Industria Chimica SpA Creation of the Bracco Foundation Direct presence of Bracco in South Korea, Scandinavia, Estonia, Czech Republic, Poland, Slovakia, Argentina, Brazil and Mexico Acquisition of Swiss Medical Care (now Bracco Injeneering), productions facilities in Singen (Germany) and Silicon Valley Medical Instruments, Inc. (SVMI) to enlarge its solutions for intravascular procedures 1981 Establishment of Bracco Research SA in Geneva focused on contrast agents for ultrasound 1990 Acquisition of Squibb Diagnostics in the US and establishment of Bracco Diagnostics Inc. in New Jersey 2001 Opening of new laboratories in Bioindustry Park Canavese (Ivrea) Direct presence in Belgium, France, Germany, Luxembourg and The Netherlands Acquisition of E-Z-EM, a leading manufacturer of radiology injectors and medical devices

5 Bracco Imaging Product Portfolio X-ray/CT Magnetic Resonance Ultrasound Nuclear Medicine CONTRAST AGENTS Contrast Agents to improve the imaging procedures, making easier the detection and characterization of pathologies MEDICAL DEVICES Devices and disposables to make easier, safer and effective the execution of diagnostic procedures INJECTORS FOR ADMINISTERING CONTRAST AGENTS Top class injectors to optimize the administration of contrast agents, assuring safety and efficacy SOLUTIONS Optimization of clinical protocols Workflow improvement Quantification Toolbox Decision Support System 5

Bracco s footprint CANADA ITALY 1 R&D Center 3 Plants

presence Commercial Indirect presence Imaging R&D Centers

Sales in more than 100 markets, direct presence in 25

6 Bracco s footprint CANADA ITALY 1 R&D Center 3 Plants GERMANY SWITZERLAND 2 R&D Centers Commercial Direct presence Commercial Indirect presence Imaging R&D Centers Cardiovascular R&D Centers JAPAN USA 3 R&D Centers CHINA Sales in more than 100 markets, direct presence in 25 countries 6 R&D Centers (3 Imaging + 3 Cardiovascular) 9 Production Plants 6

7 Bracco Imaging and ETPN Bracco Imaging has a quite long experience in the development and translation of nano/micro in vivo diagnostics We have a strong know-how in liposomes, mixed micelles, lipocelles, lipid nanoparticles and microbubbles formulations. We have in our current R&D pipeline several projects from discovery to clinical development based on nano/micro technologies. We know quite well the difficulties and pitfalls along the translation pathway of nano/micro sized contrast agents: we could help the ETPN on this base and with our extensive network of collaborations in the field 7

AUSTRIA. Table 1. FDI flows in the host economy, by geographical origin. (Millions of US dollars)

AUSTRIA. Table 1. FDI flows in the host economy, by geographical origin. (Millions of US dollars) Table 1. FDI flows in the host economy, by geographical origin World 5 690 138 6 195 3 184 10 784 7 933 31 154 6 858 9 303 840 10 618 5 760 Developed economies 5 740 13 5 341 2 689 10 137 6 291 29 721